Study the effect of concomit administration of metformin and L-carnitine on ultrasound scoring and fiver enzymes in patients with non-alcoholic fatty liver disease

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) involves a range of liver lesions that occur due to the accumulation of fat in the liver cells, leading to advanced destruction of the liver parenchyma, leading to fibrosis and hepatic cirrhosis. There is a strong relationship between this disease and insulin resistance and oxidative stress, so insulin sensitivity enhancers and antioxidants can be used to treat it. Objective: To evaluate the efficacy of concomitant administration of L-carnitine and Vitamin E compared with concomitant administration of metformin and vitamin E on grade ultrasound and liver enzymes in patients with non-alcoholic fatty liver. Methods: This study is a randomized clinical trial in which 68 patients were randomly selected and divided into two intervention groups. One group of patients received L-carnitine with Vit E and the other group received metformin with vit E for 6 months daily. Participants in the study were in the range of 18 to 65 years with confirmed NAFLD based on ultrasound results and clinical trials. Drug-sensitive, pregnant, lactating, and alcohol abusers have been excluded from the study. Results: Metformin and vitamin E decreased the fatty liver grade. In the L-carnitine group, FBS marker changes were significant and the changes were incremental. BMI was significantly higher in the L-carnitine group at two different time intervals (3 months and at the end of the study) than in the metformin group. Only the FBS marker at the end of the study was higher in the L-carnitine group than in the metformin group. Scr at baseline and after 3 months in the L-carnitine group was higher than the metformin group. Conclusion: Simultaneous administration of metformin and vitamin E is more effective than l-carnitine and vitamin E in reducing liver ultrasound grade.